Get the latest news, insights, and market updates on HROW (Harrow, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Discover 3 Elite Growth Stocks With Significant Insider Ownership
As the U.S. stock market begins a holiday-shortened week with gains across major indexes, driven by advancements in tech shares and record highs in gold and silver, investors are keenly observing the shifts and opportunities within this vibrant economic landscape. In such an environment, growth companies with significant insider ownership can offer unique insights into potential long-term value creation, as insiders often have strong confidence in their firm's prospects. Dec 22, 2025 - $HROW
Eye Drops Maker Sets Up After Strategic Buy; Sales Outlook Strong
Several biotech stocks have been earning spots on the growth IBD 50 list lately. A lesser-known name on the list, Harrow, is noteworthy as it approaches a buy point in a clearly formed base amid a quarterly swing to profit and guidance for full-year revenue growth. Harrow has formed a cup base with a buy point of 50.72, according to IBD MarketSurge. Dec 9, 2025 - $HROW
How the Narrative Surrounding Harrow Is Evolving After Analyst Target Upgrades
Harrow’s latest price target update leaves its fair value estimate essentially unchanged at about $70.63 per share, even as the underlying narrative around the stock grows more dynamic. With analysts refining their models in response to new data points, these subtle adjustments reflect a deeper reassessment of Harrow’s revenue potential and risk profile. Read on to see how you can track these evolving targets and stay prepared for the next developments in Harrow’s story. Analyst Price Targets... Dec 6, 2025 - $HROW
How CVS Elevating Vevye To Tier 1 Coverage At Harrow (HROW) Has Changed Its Investment Story
Harrow, Inc. has secured a key win as CVS’s pharmacy benefit manager replaced Xiidra with Harrow’s dry eye drug Vevye on its Tier 1 formulary, and the company recently presented at BTIG Ophthalmology Day and the Piper Sandler Healthcare Conference in New York. This formulary upgrade at the largest U.S. PBM could materially improve patient access and prescription volumes for Vevye, reinforcing Harrow’s position in branded ophthalmic pharmaceuticals. We’ll now examine how CVS elevating Vevye... Dec 3, 2025 - $HROW
A Fresh Look at Harrow (HROW) Valuation Following Recent Revenue Growth and Long-Term Performance
Harrow (HROW) continues to draw attention as investors weigh its recent performance and financial growth. The company has posted revenue growth over the past year, which has fueled conversations about its ability to navigate the evolving pharmaceutical landscape. See our latest analysis for Harrow. Harrow shares have gained momentum lately, driven by renewed optimism around its growth trajectory and recent revenue gains. The stock’s 12.2% year-to-date share price return stands in contrast to... Nov 26, 2025 - $HROW
Harrow to Present at Two Investor Conferences in December
NASHVILLE, Tenn., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will participate in the following two investor conferences in December: BTIG 5th Annual Ophthalmology Day (Virtual)Format: Fireside chatDate/Time: Monday, December 1, 2025, at 8:30 AM EST Piper Sandler 37th Annual Healthcare Conference (New York, NY)Format: Fireside chatDate/Time: Tuesday, December 2, 2025, at 3 Nov 24, 2025 - $HROW
Harrow Announces Closing of Acquisition of Melt Pharmaceuticals
NASHVILLE, Tenn., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has completed the acquisition of Melt Pharmaceuticals, Inc. (Melt), a clinical-stage pharmaceutical company pioneering non-opioid, non-IV therapies for sedation for medical procedures in the hospital, outpatient, and in-office settings. Melt’s product candidates, MELT-210, MELT-300, and MELT-400, are based on the propri Nov 18, 2025 - $HROW
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple